Age at sampling and sex distribution of AChRAb vs. MuSKAb myasthenia gravis in a large Greek population.


Journal

Clinical neurology and neurosurgery
ISSN: 1872-6968
Titre abrégé: Clin Neurol Neurosurg
Pays: Netherlands
ID NLM: 7502039

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 05 04 2021
revised: 22 07 2021
accepted: 24 07 2021
pubmed: 4 8 2021
medline: 28 1 2022
entrez: 3 8 2021
Statut: ppublish

Résumé

Myasthenia gravis (MG) is a typical B-cell-mediated neuromuscular junction disease that can be classified into seropositive and seronegative subtypes. Association of patients' age at sampling and sex with the two major seropositive MG subcategories, i.e., MGs linked to antibodies directed against the acetylcholine receptor (AChRAb) and against the muscle-specific kinase (MuSKAb), has not been compared in a large population. We performed a retrospective analysis of samples from patients with MG in Greece who underwent neurochemical diagnostic evaluation between January 2, 2013, and August 31, 2016. Overall, 1620 adult (623 male and 997 female patients; male-to-female ratio = 0.62) and 51 pediatric patients were found to be seropositive for MG. The distributions in both male and female patients were bimodal in the total and AChRAb MG cases but not in the total MuSKAb MG cases. Significant differences in the age at sampling distribution between the male and female adult patients were observed only in the AChRAb MG subtype. Significant differences between the AChRAb and MuSKAb MG categories were noted in the mean age values (60.10 and 51.49 years, respectively, for female and 65.69 and 56.19 years, respectively, for male adult patients). Our findings confirm an uneven profile of age at sampling and sex between the AChRAb and MuSKAb MG cases in a large population. Future mechanistic studies can elucidate the cause of these differences. Moreover, clinical studies can explore how such differences can affect MG treatment and prognosis.

Identifiants

pubmed: 34343914
pii: S0303-8467(21)00376-0
doi: 10.1016/j.clineuro.2021.106847
pii:
doi:

Substances chimiques

Autoantibodies 0
Receptors, Cholinergic 0
MUSK protein, human EC 2.7.10.1
Receptor Protein-Tyrosine Kinases EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106847

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Maria Belimezi (M)

Diagnostic Services Laboratory, Hellenic Pasteur Institute, Athens, Greece.

Antonios Kalliaropoulos (A)

Diagnostic Services Laboratory, Hellenic Pasteur Institute, Athens, Greece.

Juan Jiménez (J)

ADEMA Universitary School, University of the Balearic Islands (UIB), Palma, Balearic Islands, Spain.

Irene Garcia (I)

Department of Mathematical Sciences and Informatics, and Health Research Institute (IdISBa), University of the Balearic Islands (UIB), Palma, Balearic Islands, Spain.

Alexios-Fotios A Mentis (AA)

Diagnostic Services Laboratory, Hellenic Pasteur Institute, Athens, Greece; University Research Institute of Maternal and Child Health and Precision Medicine, National and Kapodistrian University of Athens, Levadias, Athens, Greece. Electronic address: amentis1@jhu.edu.

George P Chrousos (GP)

University Research Institute of Maternal and Child Health and Precision Medicine, National and Kapodistrian University of Athens, Levadias, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH